All In Biotech

Drug Trial Radar · NCT03901469

A Study of ZEN003694 and Talazoparib in Patients With Triple Negative Breast Cancer

A Phase 2b Study of ZEN003694 in Combination With Talazoparib in Patients With Triple-Negative Breast Cancer

Last checked: Nov 19, 2026Latest source record: Oct 7, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

TerminatedResults posted on the registry

Status

Terminated

Enrollment

115

Actual

Start

Jun 26, 2019

Primary completion

Mar 7, 2024

Study completion Mar 7, 2024

Sponsor

Lead sponsor
Zenith EpigeneticsIndustry
Sponsor type
Industry
Collaborators
Pfizer; Newsoara Biopharma Co., Ltd.
First posted
Apr 3, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a two-part open label, non-randomized, Phase 2, study of ZEN003694 in combination with Talazoparib in patients with TNBC without germline mutations of BRCA1 or BRCA2. Part 1 is a dose escalation and Part 2 is a Simon 2-Stage design. There are 3 expansion cohorts: Expansion Cohort A (combination treatment in post-TROP2-ADC patients), Expansion Cohort B (ZEN003694 monotherapy), and Expansion Cohort C (combination treatment in TROP2-ADC-naive patients).

Conditions

  • Triple Negative Breast Cancer

Interventions

  • ZEN003694Drug

    PO QD

  • TalazoparibDrug

    PO QD

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Part 1 and Part 2: Number of Participants With Treatment-related Adverse Events (AE) and Treatment-related Serious Adverse Events (SAE)Time frame: Cycle 1 Day 1 to 30 days post last dose (each cycle is 28 days) up to 22 months
  2. Part 1: Number of Participants With Dose-limiting Toxicities (DLT)Time frame: Cycle 1, Up to 1 month
  3. Part 2: Clinical Benefit Rate (CBR)Time frame: From screening up to 18 months
  4. Expansion Cohort A: Objective Response Rate (ORR) by RECIST v1.1 (CR or PR)Time frame: From screening up to 18 months

Locations

19 sites in 4 countries. Site status is shown where the registry gives one.

  • Banner MD Anderson Cancer Center

    Gilbert, Arizona

  • Emory University Winship Cancer Institute

    Atlanta, Georgia

  • University of Kansas Cancer Center

    Westwood, Kansas

  • Dana Farber Cancer Institute

    Boston, Massachusetts

  • Memorial Sloan Kettering Cancer Center

    New York, New York

  • University of Pennsylvania

    Philadelphia, Pennsylvania

  • Tennessee Oncology (Sarah Cannon)

    Nashville, Tennessee

  • MD Anderson

    Houston, Texas

  • Institut Jules Bordet

    Anderlecht, Belgium

  • UZ Leuven

    Leuven, Belgium

  • The First Affiliated Hosptial of Bengbu Medical College

    Bengbu, Anhui, China

  • Sun Yat-sen University Cancer Center

    Guangzhou, Guangdong, China

  • Sun Yat-sen Memorial Hospital, Sun Yat-sen University

    Guangzhou, Guangdong, China

  • Hunan Cancer Hospital

    Changsha, Hunan, China

  • Affliated Hospital of Jining Medical University

    Jining, Shandong, China

  • The Second People's Hospital of Neijiang

    Neijiang, Sichuan, China

  • Tianjing Medical University Cancer Institute & Hospital

    Tianjin, Tianjin Municipality, China

  • Vall d'Hebron Institute of Oncology (VHIO)

    Barcelona, Spain

  • START Madrid

    Madrid, Spain

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.